Global /India /Healthcare /Drug Manufacturers - Specialty & Generic /ZYDUSLIFE
chevron_leftBack

Zydus Lifesciences Ltd.

ZYDUSLIFE
NSE: ZYDUSLIFE Delayed
868.00INR 1.8%
10.15 USD
As of 24 April 2025, Zydus Lifesciences Ltd. has a market cap of $10.06B USD, ranking #1690 globally and #117 in India. It ranks #150 in the Healthcare sector, and #20 in the Drug Manufacturers - Specialty & Generic industry.
Global Rank
1690
Country Rank
117
Sector Rank
150
Industry Rank
20
Key Stats
Market Cap
$10.06BUSD
858.02B INR
Enterprise Value
$10.04BUSD
858.27B INR
Revenue (TTM)
$2.61BUSD
222.47B INR
EBITDA (TTM)
$727.2MUSD
62.18B INR
Net Income (TTM)
$531.69MUSD
45.37B INR
EBITDA Margin
28%
Profit Margin
20%
PE Ratio
18.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Sharvil Patel open_in_new
Employees
26,921
Founded
1952
Website
zyduslife.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
1.8% 6.1% -5.1% -11% -12% -9.1%
Upcoming Earnings
Earnings Date
Fri, May 16

Markets

Exchange Ticker Price
National Stock Exchange of India
MIC: XNSE
PRIMARY
ZYDUSLIFE
Zydus Lifesciences Ltd
ISIN: INE010B01027
Shares Out.:
1.006B1 Shares Float: 251.769M2
TV:
SA:
YF:
GF:
BA:
MS:
868.00 INR
Bombay Stock Exchange
MIC: XBOM
532321 (ZYDUSLIFE)
Zydus Lifesciences Ltd
ISIN: INE010B01027
TV:
SA:
YF:
GF:
BA:
MS:
831.40 INR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Zydus Lifesciences Ltd.

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (India)
Name
Market Cap diff.
Sun Pharmaceutical Industries Ltd.
SUNPHARMA
$49.13B
4.19T INR
389%
Divi's Laboratories Ltd.
DIVISLAB
$18.39B
1.57T INR
83%
Cipla Ltd.
CIPLA
$14.46B
1.23T INR
44%
Torrent Pharmaceuticals Ltd.
TORNTPHARM
$13.23B
1.13T INR
32%
Mankind Pharma Ltd.
MANKIND
$12.47B
1.06T INR
24%
Industry: Drug Manufacturers - Specialty & Generic (Global)
Name
Market Cap diff.
Zoetis Inc.
ZTS
$67.32B
569%
Merck KGaA
MRK
$59.42B
52.43B EUR
491%
Takeda Pharmaceutical Company Ltd.
4502
$46.31B
6.6T JPY
361%
Haleon plc
HLN
$45.57B
34.34B GBP
353%
Galderma Group AG
GALD
$23.06B
19.13B CHF
129%